1. Scrip
  2. >>New Products

Biosimilar Humira Blocked Until 2023, But Time Could Clear Commercial Path

 
• By Jessica Merrill

Amgen settled patent infringement litigation with AbbVie, allowing its Humira biosimilar Amjevita to launch in Europe in October 2018, but blocking entry in the US until 2023. The deal could set a bar for other Humira biosimilar developers.

Patent Law Concept 3D Illustration

AbbVie Inc. scored an important win in its all-important effort to extend the exclusivity of its top-selling blockbuster Humira (adalimumab) for several more years through a patent infringement settlement with its primary challenger, Amgen Inc. The agreement announced Sept. 28 will block US entry of Amgen's adalimumab biosimilar, Amjevita, until Jan. 31, 2023, although it will allow for the biosimilar to launch in Europe on Oct. 16, 2018.

The companies agreed to dismiss ongoing patent litigation, with AbbVie granting Amgen patent licenses for the use and sale of Amjevita worldwide on a country-by-country basis. In exchange, Amgen will...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

More from Scrip

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.

Sweden’s Hansa Slims Down Ahead of Key Readouts

 
• By Kevin Grogan

New CEO Renée Aguiar-Lucander is marking her mark.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.